Codexis, Inc. (NASDAQ:CDXS) SVP James Lalonde sold 19,999 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $18.65, for a total transaction of $372,981.35. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of CDXS traded up $0.19 during mid-day trading on Thursday, reaching $19.56. 12,619 shares of the stock traded hands, compared to its average volume of 393,244. The firm has a market capitalization of $1.08 billion, a P/E ratio of -93.38 and a beta of -0.37. Codexis, Inc. has a 12-month low of $12.85 and a 12-month high of $23.05. The company has a quick ratio of 3.38, a current ratio of 3.42 and a debt-to-equity ratio of 0.51.

Codexis (NASDAQ:CDXS) last issued its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.09). The business had revenue of $15.58 million during the quarter, compared to analyst estimates of $14.83 million. Codexis had a negative net margin of 18.22% and a negative return on equity of 21.08%. Equities analysts expect that Codexis, Inc. will post -0.23 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in CDXS. Quantamental Technologies LLC bought a new stake in Codexis during the fourth quarter worth approximately $26,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Codexis by 152.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,837 shares of the biotechnology company’s stock worth $47,000 after buying an additional 1,711 shares in the last quarter. NumerixS Investment Technologies Inc acquired a new position in shares of Codexis during the 1st quarter worth $66,000. Advisor Group Inc. raised its holdings in shares of Codexis by 184.2% during the 1st quarter. Advisor Group Inc. now owns 3,342 shares of the biotechnology company’s stock worth $69,000 after buying an additional 2,166 shares in the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. raised its holdings in shares of Codexis by 236.5% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,375 shares of the biotechnology company’s stock worth $91,000 after buying an additional 3,075 shares in the last quarter. Hedge funds and other institutional investors own 85.74% of the company’s stock.

Several brokerages recently weighed in on CDXS. BidaskClub raised shares of Codexis from a “hold” rating to a “buy” rating in a research note on Tuesday, May 7th. ValuEngine upgraded shares of Codexis from a “buy” rating to a “strong-buy” rating in a research note on Monday, April 1st. Zacks Investment Research upgraded shares of Codexis from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a research note on Thursday, January 17th. Craig Hallum lifted their price objective on shares of Codexis from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, February 27th. Finally, HC Wainwright lifted their price objective on shares of Codexis to $22.50 and gave the company a “buy” rating in a research note on Monday, March 4th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Codexis currently has an average rating of “Buy” and an average price target of $21.07.

WARNING: This piece was originally reported by Marea Informative and is the sole property of of Marea Informative. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.mareainformativa.com/news/2019/05/16/codexis-inc-cdxs-svp-sells-372981-35-in-stock.html.

About Codexis

Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.

Featured Article: How to track put option volume

Insider Buying and Selling by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.